{"nctId":"NCT01768286","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection","startDateStruct":{"date":"2013-01"},"conditions":["Chronic Hepatitis C Virus"],"count":441,"armGroups":[{"label":"LDV/SOF 12 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 12 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]},{"label":"LDV/SOF 24 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 24 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7997"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\> 18, with chronic genotype 1 HCV infection\n* HCV treatment-experienced, including patients who have previously failed a nonstructural protein (NS)3/4A protease inhibitor plus pegylated interferon (PEG)/RBV regimen\n* HCV RNA \\> 10,000 IU/mL at screening\n* Cirrhosis determination; a liver biopsy may be required\n* Screening laboratory values within defined thresholds\n* Use of two effective contraception methods if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Pregnant or nursing female or male with pregnant female partner\n* Coinfection with HIV or hepatitis B virus\n* Current or prior history of clinical hepatic decompensation\n* Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers)\n* Chronic use of systemic immunosuppressive agents\n* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) 12 weeks following the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"99.1","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug","description":"The percentage of participants who experienced an adverse event leading to permanent discontinuation from any study drug was summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"99.1","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"20.2","spread":null},{"groupId":"OG003","value":"29.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null},{"groupId":"OG001","value":"82.9","spread":null},{"groupId":"OG002","value":"81.7","spread":null},{"groupId":"OG003","value":"83.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"99.1","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.57","spread":"0.501"},{"groupId":"OG001","value":"-4.50","spread":"0.540"},{"groupId":"OG002","value":"-4.47","spread":"0.569"},{"groupId":"OG003","value":"-4.50","spread":"0.575"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.08","spread":"0.443"},{"groupId":"OG001","value":"-4.94","spread":"0.520"},{"groupId":"OG002","value":"-4.99","spread":"0.571"},{"groupId":"OG003","value":"-4.99","spread":"0.617"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":"0.439"},{"groupId":"OG001","value":"-5.02","spread":"0.543"},{"groupId":"OG002","value":"-5.06","spread":"0.571"},{"groupId":"OG003","value":"-5.04","spread":"0.779"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":"0.439"},{"groupId":"OG001","value":"-5.02","spread":"0.544"},{"groupId":"OG002","value":"-5.06","spread":"0.571"},{"groupId":"OG003","value":"-5.08","spread":"0.605"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as on-treatment virologic failure or virologic relapse.\n\n* On-Treatment Virologic Failure was defined as\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n\nVirologic relapse was defined as confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Arthralgia"]}}}